These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 3365915)
41. Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time. Ziegler VE; Biggs JT; Rosen SH; Meyer DA; Preskorn SH J Clin Psychiatry; 1978 Aug; 39(8):660-3. PubMed ID: 681303 [TBL] [Abstract][Full Text] [Related]
42. Persistent impairment of clomipramine demethylation in recently detoxified alcoholic patients. Balant-Gorgia AE; Gay M; Gex-Fabry M; Balant LP Ther Drug Monit; 1992 Apr; 14(2):119-24. PubMed ID: 1585395 [TBL] [Abstract][Full Text] [Related]
43. Dosage optimization methods applied to imipramine and desipramine in enuresis treatment. Tamayo M; Fernández de Gatta MM; García MJ; Domínguez-Gil A J Clin Pharm Ther; 1992 Feb; 17(1):55-9. PubMed ID: 1548314 [TBL] [Abstract][Full Text] [Related]
44. Effect of phenobarbitone on the distribution and elimination of imipramine in rats. Lin TH; Sawada Y; Sugiyama Y; Iga T; Hanano M J Pharm Pharmacol; 1985 Oct; 37(10):735-8. PubMed ID: 2867146 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review. Ereshefsky L; Tran-Johnson T; Davis CM; LeRoy A Clin Chem; 1988 May; 34(5):863-80. PubMed ID: 3286056 [TBL] [Abstract][Full Text] [Related]
48. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Mason BJ; Kocsis JH; Ritvo EC; Cutler RB JAMA; 1996 Mar; 275(10):761-7. PubMed ID: 8598592 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice. Wyska E; Szymura-Oleksiak J; Opoka W; Baś B; Niewiara E; Pomierny L; Dybała M; Nowak G Pol J Pharmacol; 2004; 56(4):479-84. PubMed ID: 15520504 [TBL] [Abstract][Full Text] [Related]
50. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. Perry PJ; Zeilmann C; Arndt S J Clin Psychopharmacol; 1994 Aug; 14(4):230-40. PubMed ID: 7962678 [TBL] [Abstract][Full Text] [Related]
51. Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. Sato Y; Shibanoki S; Sugahara M; Ishikawa K Br J Pharmacol; 1994 Jun; 112(2):625-9. PubMed ID: 8075879 [TBL] [Abstract][Full Text] [Related]
52. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Skjelbo E; Brøsen K; Hallas J; Gram LF Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236 [TBL] [Abstract][Full Text] [Related]
53. Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. Hrdina PD; Rovei V; Henry JF; Hervy MP; Gomeni R; Forette F; Morselli PL Psychopharmacology (Berl); 1980; 70(1):29-34. PubMed ID: 6775331 [TBL] [Abstract][Full Text] [Related]
54. Population pharmacokinetics of imipramine in children. Tamayo M; Fernández de Gatta MM; García MJ; Domínguez-Gil A Eur J Clin Pharmacol; 1992; 43(1):89-92. PubMed ID: 1505617 [TBL] [Abstract][Full Text] [Related]
55. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Sandor P; Sellers EM; Dumbrell M; Khouw V Clin Pharmacol Ther; 1981 Sep; 30(3):390-7. PubMed ID: 7273603 [TBL] [Abstract][Full Text] [Related]
56. Vinpocetine therapy does not change imipramine pharmacokinetics in man. Hitzenberger G; Schmid R; Braun W; Grandt R Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):99-104. PubMed ID: 2318551 [TBL] [Abstract][Full Text] [Related]
57. Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. Yoo SD; Holladay JW; Fincher TK; Baumann H; Dewey MJ J Pharmacol Exp Ther; 1996 Mar; 276(3):918-22. PubMed ID: 8786570 [TBL] [Abstract][Full Text] [Related]
58. Desipramine clearance in children and adolescents: absence of effect of development and gender. Cohen LG; Biederman J; Wilens TE; Spencer TJ; Mick E; Faraone SV; Prince J; Flood JG J Am Acad Child Adolesc Psychiatry; 1999 Jan; 38(1):79-85. PubMed ID: 9893420 [TBL] [Abstract][Full Text] [Related]
59. Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Roberts RK; Desmond PV; Wilkinson GR; Schenker S Clin Pharmacol Ther; 1979 Jun; 25(6):826-31. PubMed ID: 445949 [TBL] [Abstract][Full Text] [Related]